FDA Clearance Tracker · P870024-S060
FluoroPerm30 (paflufocon C), FluoroPerm60 (paflufocon B), FluoroPerm92 (paflufocon A), Paragon HDS (paflufocon B) Rigid
Last checked: Nov 20, 2026Latest source record: Jun 16, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jun 16, 2022
Approved
Time to decision
87 days
Received Mar 21, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P870024-S060
- Device name
- FluoroPerm30 (paflufocon C), FluoroPerm60 (paflufocon B), FluoroPerm92 (paflufocon A), Paragon HDS (paflufocon B) Rigid
- Applicant
- CooperVision, Inc.
- Applicant location
- San Ramon, CA
- Received
- Mar 21, 2022
- Decided
- Jun 16, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P870024
Device type
- Device class
- Class III
- Regulation
- 21 CFR 886.5916
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for a new manufacturing site, Paragon Vision Sciences. Inc. located at 2120 W. Guadalupe Rd. Gilbert, Arizona 85233. This facility is responsible for manufacturing of the contact lens materials and finished lenses, shipping, R&D, and administration.
Source documents
Other decisions for CooperVision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K234127 · Decided Jan 25, 2024 · 28 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.